Monkeys with nigrostriatal lesions effects of monoaminergic drugs.
D000596:Amino Acids / Q000627:therapeutic use; D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology; D001058:Apomorphine / Q000494:pharmacology; D001679:Biogenic Amines / Q000378:metabolism; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D065098:Catechol O-Methyltransferase Inhibitors; D002522:Chlorocebus aethiops; D003342:Corpus Striatum / Q000502:physiology*; D004347:Drug Interactions; D000882:Haplorhini; D006246:Harmaline; D007980:Levodopa / Q000494:pharmacology / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D009069:Movement Disorders / Q000139:chemically induced; D013378:Substantia Nigra / Q000502:physiology*; D014202:Tremor / Q000139:chemically induced / Q000188:drug therapy
D000596:Amino Acids; D000978:Antiparkinson Agents; D001679:Biogenic Amines; D065098:Catechol O-Methyltransferase Inhibitors; D008996:Monoamine Oxidase Inhibitors; D007980:Levodopa; D006246:Harmaline; D002262:Carboxy-Lyases; D001058:Apomorphine